01135nas a2200145   4500008004100000024000700041245003000048210002900078260001900107300001000126490000700136520076400143100001800907856006400925       2023                        eng d  a0400aDrug Review: Daridorexant0 aDrug Review Daridorexant  cSeptember 2023  a90-910 v123 a<p class="rtejustify">Registrations: had been registered in the following countries United States of America (USA), United Kingdom (U.K.), Canada, and Saudi Arabia (SA). Trade name (USA.); QUVIVIQ® Registration number (S.A.); Not Available. Insurance Drug Formulary (S.A.); Not covered (28.1.2023). General Information: Registered Company: Idorsia Pharmaceuticals, Ltd. Regulatory Status: R.X. Mechanism of Action: The treatment of insomnia is presumed to be through the antagonism of orexin receptors. In addition, the orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive. <strong>Read more...</strong></p>
1 aAlsaab, Juman  uhttps://www.ijphs.org/article/2023/12/2/105530ijpcs20231211